ReviewActa physiologica (Oxford, England)2026
The Neurovascular Niche: A Gathering Venue for Neuroinflammation and Remyelination in Multiple Sclerosis.
Review in Acta physiologica (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In the central nervous system (CNS), the tissue microenvironment is continuously monitored and regulated to secure the unobstructed function of neurons and of their networks. This is a key function of the neurovascular niche (NVN), which is the interface between the cells of the nervous tissue and the cells and the content of blood vessels. It is enabled by the Blood-Brain Barrier, a structure formed by endothelial and perivascular cells, extracellular matrix, and astrocytes, and is manifested by the limited surveillance of the CNS from blood-derived cells. Multiple sclerosis (MS) is a devastating degenerative disorder, in which the myelin sheaths that enwrap neuronal axons are destroyed, leading, over time, to neurological symptoms. MS has a strong immunological component which is targeted in most of the current disease-modifying treatments. Nevertheless, regenerative interventions aiming at enhancing and restoring the endogenous remyelination potential of the CNS, driven by the abundant Oligodendrocyte Progenitor Cells (OPCs), have not been successfully developed so far. Here, we will review key information on the structure of the NVN, and we will summarize the evidence on the role of inflammation in the emergence and the progress of MS, with a focus on the active response of OPCs. We will also present recent experimental evidence on the role of less investigated cellular elements of the NVN, such as pericytes and platelets, in the regulation of OPCs. Finally, we will discuss current and future treatments for MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.